Dr. Reddy's Laboratories Has Licensing Deal for Potential Multiple Myeloma Treatment

MT Newswires Live

Feb 06, 2025

Dr. Reddy's Laboratories (RDY) said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.

The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.

Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.

HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson.

Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson & Johnson fell 0.5%.

Price: 13.99, Change: +0.01, Percent Change: +0.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509051662"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509051662\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509051662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509051662","market":"hk","top_or_hot":-1,"title":"Dr. Reddy's Laboratories Has Licensing Deal for Potential Multiple Myeloma Treatment","media":"MT Newswires Live","content":"<html><body><p> Dr. Reddy's Laboratories (RDY) said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.</p><p>The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.</p><p>Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.</p><p>HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson &amp; Johnson.</p><p>Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson &amp; Johnson fell 0.5%.</p><p>Price: 13.99, Change: +0.01, Percent Change: +0.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr. Reddy's Laboratories Has Licensing Deal for Potential Multiple Myeloma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr. Reddy's Laboratories Has Licensing Deal for Potential Multiple Myeloma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-06 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dr. Reddy's Laboratories (RDY) said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.</p><p>The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.</p><p>Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.</p><p>HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson &amp; Johnson.</p><p>Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson &amp; Johnson fell 0.5%.</p><p>Price: 13.99, Change: +0.01, Percent Change: +0.11</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1244550494.USD","symbol_name":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509051662","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509051662","pubTimestamp":1738857454,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dr. Reddy's Laboratories  said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson.Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson & Johnson fell 0.5%.Price: 13.99, Change: +0.01, Percent Change: +0.11","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","RDY":"如瑞迪博士","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","JNJ":"强生","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","RDY.AU":"READYTECH HOLDINGS LTD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","BK4557":"大麻股","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4592":"伊斯兰概念","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK7016":"应用软件","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4523":"印度概念","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","BK4581":"高盛持仓","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4534":"瑞士信贷持仓","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD"},"translate_title":"雷迪博士的实验室达成了潜在多发性骨髓瘤治疗的许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY.AU":1,"RDY":0.9,"JNJ":0.9},"content_text":"Dr. Reddy's Laboratories (RDY) said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson.Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson & Johnson fell 0.5%.Price: 13.99, Change: +0.01, Percent Change: +0.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}